Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 9, 2007, Pages 1095-1101

  Torer, Nihan ^a,b   Ozenirler, Seren ^a   Yucel, Aysegul ^a   Bukan, Neslihan ^a   Erdem, Ozlem ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Bax; Bcl 2; IL 6; IL 8; MDA; NASH; NO; TGF ; TNF

Indexed keywords

CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; MALONALDEHYDE; NITRIC OXIDE; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOPSY; CONTROLLED STUDY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; BCL-2-ASSOCIATED X PROTEIN; BIOLOGICAL MARKERS; BIOPSY; CYTOKINES; FATTY LIVER; FEMALE; FIBROSIS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIVER FUNCTION TESTS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548126148     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701286680     Document Type: Article

References (37)

1. Sleisenger F. Nonalcoholic steatohepatitis: gastrointestinal and liver disease. 7th ed. Philadelphia: Saunders; 2002;2:1393-400.
2. Harrison SA. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002;97:2714-24.
3. Neuschwander-tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202-19.
4. Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999;19:221-9.
5. Agrawal S, Bonkovsky HL. Management of nonalcoholic steatohepatitis. J Clin Gastroenterol 2002;35:253-61.
6. Lin HZ, Yang SQ. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach. Am J Gastroenterol 2003;98:2093-7.
7. Lieber CS, Leo MA. Model of nonalcoholic steatohepatitis. Am J Clin Nutr 2004;79:502-9.
8. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002;34:255-62.
9. Metha K, VanThiel DH. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002;60:289-93.
10. Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs 2003;63:2379-94.
11. Day CP, James OFW. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-5.
12. Chitturi S, Farrel GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
13. Kleiner DE, Brunt EM. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
14. Walsh MJ, Vanags DM, Clouston AD. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004;39:1230-8.
15. Yin M, Wheeler MD, Kono H. Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-52.
16. McClain CJ, Hill D. Cytokines and alcoholic liver disease. Semin Liver Dis 1993;13:170-82.
17. Yang SQ, Lin HZ. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997;94:2557-62.
18. Jaeschke H, Gores GJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65:166-76.
19. Soloman SS, Mishra SK. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res 1997;29:370-82.
20. Satapathy SK, Garg S, Chauhan R. Beneficial effects of tumor necrosis factor-a inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1946-52.
21. Adams LA, Zein CO. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:2365-8.
22. Koppe SWP, Sahai A, Malladi P. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J. Hepatol 2004;41:592-8.
23. Hui JM, Hodge A. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
24. Bahcecioglu IH, Yalniz M. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2005;52:1549-53.
25. Starkel P, Sempoux C, Leclercq I. Oxidative stress, KLF6 and transforming growth β up-regulation differentiate nonalcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol 2003;39:538-46.
26. Sepulveda-Flores RN, Vera-Cabrera L. Obesity-related nonalcoholic steatohepatitis and TGF-beta 1 serum levels in relation to morbid obesity. Ann Hepatol 2002;1:36-9.
27. Kugelmas M, Hill DB. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-9.
28. Koruk M, Taysi S. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci 2004;34:57-62.
29. Fierbinteanu-Braticevici C, Bengus A. The risk factors of fibrosis in nonalcoholic steatohepatitis. Rom J Intern Med 2002;40:81-8.
30. Bahcecioglu IH, Yalniz M. Levels of serum vitamin A, alpha-tocopherol and malondialdehyde in patients with nonalcoholic steatohepatitis: relationship with histopathologic severity. Int J Clin Pract Mar 2005;59:318-23.
31. Kanzler S, Galle PR. Apoptosis and liver. Semin Cancer Biol 2000;10:173-84.
32. Rashid A, Wu T-C, Huang C-C. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 1999;29:1131-8.
33. Tsamandas AC, Thomopoulos K. Potential role of Bcl-2 and Bax mRNA and protein expression in chronic hepatitis type B and C: a clinicopathologic study. Modern Pathol 2003;16:1273-88.
34. Sorenson CM. Bcl-2 family members and disease. Biochimica Biophysica Acta 2004;1644:169-77.
35. Frommel TO, Yong S. Immunohistochemical evaluation of Bcl-2 gene family expression in liver of hepatitis C and cirrhotic patients: a novel mechanism to explain the high incidence of hepatocarcinoma in cirrhotics. Am J Gastroenterol 1999;94:178-82.
36. Laurent A, Nicco C. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology 2004;39:1277-85.
37. Ribeiro PS, Cortez-Pinto H. Hepatocyte apoptosis, expression of death receptors, and activation of NF-KB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004;99:1708-17.